Ask My Investor AI
Public company · NasdaqPublished company research
MYGN

Identity verified against SEC EDGAR filing 0000899923-26-000018; registered as MYRIAD GENETICS INC, CIK 0000899923.

Myriad Genetics

Myriad Genetics is mapped to the Women's health formalization theme as Genetic diagnostics - hereditary cancer risk (MyRisk, including hereditary breast/ovarian), prenatal and carrier screening (Foresight/Prequel), alongside non-women's-health assays (e.g., GeneSight pharmacogenomics).. Medium and partial. Hereditary breast/ovarian cancer risk, prenatal and carrier screening are women's-health-relevant, but the company is diversified across oncology and mental-health testing. Current segment revenue split was not retrieved this session. Theme materiality is stated separately and, where not independently verified, is marked accordingly.

Ask follow-up research
Reviewed company research · researched 2026-07-22 · not an individual investment recommendation
Listing
public
Ticker
MYGN
Exchange
Nasdaq
HQ
—
Currency
USD
SEC CIK
0000899923
Investment case

How this company captures the theme economics

Competitive position

Medium and partial. Hereditary breast/ovarian cancer risk, prenatal and carrier screening are women's-health-relevant, but the company is diversified across oncology and mental-health testing. Current segment revenue split was not retrieved this session. Company-specific competitive positioning is assessed at the theme level and awaits deeper primary research.

Scarce assets

Scarce assets in this value chain include reimbursement and coverage decisions (state ivf/fertility mandates, employer benefit design, cms/medicaid) - the gating variable for the whole theme., specialist capacity: reproductive endocrinologists/fertility clinics, urogynecology, maternal-fetal medicine., proprietary clinical data and validated assays/algorithms (nipt content, hpv assays, ai mammography)..

Products, segments, and customers

Myriad Genetics operates in Women's health formalization. Segment- and product-level detail is pending company-specific research.

Theme capture

Medium and partial. Hereditary breast/ovarian cancer risk, prenatal and carrier screening are women's-health-relevant, but the company is diversified across oncology and mental-health testing. Current segment revenue split was not retrieved this session.

Conditions

What must be true

  1. Latest 10-Q/10-K: women's-health (prenatal/carrier/hereditary) revenue vs GeneSight/oncology; prenatal test volumes; reimbursement status for expanded screening.
  2. The exposure described for Myriad Genetics must be confirmed as financially material in official filings.

Identifiable catalysts

  • Forthcoming quarterly and annual issuer filings
  • Theme-level catalysts detailed in the Women's health formalization brief
Theme materiality

1 mapped theme

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

Genetic diagnostics - hereditary cancer risk (MyRisk, including hereditary breast/ovarian), prenatal and carrier screening (Foresight/Prequel), alongside non-women's-health assays (e.g., GeneSight pharmacogenomics).

Women's health formalization

Medium and partial. Hereditary breast/ovarian cancer risk, prenatal and carrier screening are women's-health-relevant, but the company is diversified across oncology and mental-health testing. Current segment revenue split was not retrieved this session.

Evidence
No Myriad-specific financials fetched this task (SEC filings not retrievable in-session; search budget exhausted). Product-line relevance is established from general public positioning, not from a fetched figure.
Materiality
not assessed — Women's-health share of revenue not established from a fetched primary source this session; only qualitative product relevance is supported.
Financial evidence

Official SEC filing evidence

Reference period: FY2025.

  • Operating income$-387 million
    FY2025[1]
  • Diluted EPS$-3.95
    FY2025[1]
  • Operating cash flow$2 million
    FY2025[1]
  • Cash and equivalents$150 million
    FY2025 year-end[1]

Limitation: Filing evidence establishes scale, profitability, cash generation, and leverage. Market-derived valuation is withheld until a licensed market-data feed is connected, and theme materiality is stated separately.

Risks

Material risks and break conditions

Material risks

  • Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
  • Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.

Thesis-break conditions

  • Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
  • Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.
Investability conclusion

Where the evidence lands

Identity and filing financials are established; theme materiality is not independently verified. This is a filing-backed research profile with deeper company-specific research pending, and is not a personalized recommendation.

Next diligence

  1. Latest 10-Q/10-K: women's-health (prenatal/carrier/hereditary) revenue vs GeneSight/oncology; prenatal test volumes; reimbursement status for expanded screening.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. MYRIAD GENETICS INC FY2025 Form 10-KSEC EDGAR · primary · published 2026-02-24 · accessed 2026-07-22